NCT00275925已完成4 期
A 24-Week Prospective, Open-Label, Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Adult Patients With Partial Seizures
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 80
- 试验地点
- 14
- 主要终点
- Epileptic activity at electroencephalography in rest
研究概览
简要总结
This study is aimed to evaluate the efficacy, safety and tolerability of oxcarbazepine monotherapy in adults with partial seizures.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •males and females, 18 - 70 years of age;
- •diagnosis of epilepsy, partial seizures;
- •ineffective or intolerable present therapy with 1 antiepileptic drug, or none of previous therapy with antiepileptic drugs
排除标准
- •progressive lesion of brain revealed by CT/MRI that performed no earlier than 2 years prior to screening;
- •non-epileptic seizures;
- •drug or alcohol dependence during a year prior to screening;
- •Other protocol-defined inclusion/exclusion criteria may apply.
结局指标
主要结局
Epileptic activity at electroencephalography in rest
Flash light and hyperventilation test with electroencephalography
Frequency of epileptic episodes according to patient's diary
Electrocardiogram analysis for rhythm and conduction
Blood test for sodium, hepatic enzymes and blood cells
次要结局
- Quality of Life assessment at baseline, last visit
- Tolerability and safety of 24 week's treatment with oxcarbazepine monotherapy in adult patients with partial seizures
- Rate of patients with total and partial control of epilepsy
- Rate of patients requiring additional antiepileptic drugs
研究者
研究点 (14)
Loading locations...
相似试验
已完成
3 期
Pediatric Epilepsy StudyEpilepsyNCT00050947Novartis Pharmaceuticals94
已完成
1 期
A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on PadsevonilEpilepsyNCT03695094UCB Biopharma S.P.R.L.31
已完成
3 期
Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial EpilepsyPartial EpilepsyNCT00908349Supernus Pharmaceuticals, Inc.214
已完成
不适用
Bioequivalence Study of Oxcarbazepine Oral Suspension 300 mg/5mL Under Fed ConditionHealthyNCT00951847Ranbaxy Laboratories Limited40
已完成
3 期
Pediatric Epilepsy StudyEpilepsies, PartialEpilepsyNCT00050934Novartis Pharmaceuticals132